How Supplied
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in three different Dose Packs.
Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.
Dose Pack |
Content |
NDC |
Description |
300 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
0069-5045-30 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
| |||
0069-5321-30 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
||
Each Blister Card Contains: |
0069-5045-06 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
| |||
0069-5321-03 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
||
150 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
0069-5317-20 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Card Contains:
|
0069-5317-02 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
300 mg nirmatrelvir; 150 mg nirmatrelvir; |
Each Carton Contains: |
0069-0521-11 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Card Contains: 6 nirmatrelvir tablets |
0069-0521-11 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
How Supplied
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in three different Dose Packs.
Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.
Dose Pack |
Content |
NDC |
Description |
300 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
0069-5045-30 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
| |||
0069-5321-30 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
||
Each Blister Card Contains: |
0069-5045-06 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
| |||
0069-5321-03 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
||
150 mg nirmatrelvir; 100 mg ritonavir |
Each Carton Contains: |
0069-5317-20 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Card Contains:
|
0069-5317-02 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
|
300 mg nirmatrelvir; 150 mg nirmatrelvir; |
Each Carton Contains: |
0069-0521-11 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
Each Blister Card Contains: 6 nirmatrelvir tablets |
0069-0521-11 |
Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. |
{{section_name_patient}}
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.